| Abraxis Bioscience LLC Patent applications |
| Patent application number | Title | Published |
|---|
| 20130101504 | SPARC BINDING ANTIBODIES AND USES THEREOF - The invention provides SPARC binding antibodies that target disease sites, in particular, tumors and uses thereof to diagnose and treat diseases, in particular, cancerous tumors. | 04-25-2013 |
| 20130045240 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS - The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a hedgehog inhibitor that inhibits a hedgehog signaling pathway. | 02-21-2013 |
| 20120245089 | USE OF THE SPARC MICROENVIRONMENT SIGNATURE IN THE TREATMENT OF CANCER - The invention provides multiparametric anti-SPARC antibody-based techniques for predicting the response to therapy, including chemotherapy, radiotherapy, surgical therapy and combination therapies | 09-27-2012 |
| 20120183538 | SPARC ANTISENSE COMPOSITIONS AND USES THEREOF - The invention provides SPARC antisense oligonucleotides and methods of their use in proliferative diseases such as cancer and hepatic fibrosis. | 07-19-2012 |
| 20120087910 | SPARC ANGIOGENIC DOMAIN AND METHODS OF USE - The invention provides compositions and methods which exploit the discovery of the SPARC carboxy angiogenic domain. | 04-12-2012 |
| 20120039801 | SPARC binding peptides and uses thereof - Disclosed are SPARC and albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents In particular, compositions comprising SPARC binding peptide—Antibody Fc domain fusion proteins and methods of their use are disclosed. | 02-16-2012 |
| 20120020959 | USE OF THE SPARC MICROENVIRONMENT SIGNATURE IN THE TREATMENT OF CANCER - The invention provides multiparametric anti-SPARC antibody-based techniques for predicting the response to chemotherapy. | 01-26-2012 |
| 20120014954 | SPARC BINDING SCFVS - The invention provides compositions comprising SPARC binding ScFc and its use. | 01-19-2012 |
| 20120009123 | Albumin binding peptide-mediated disease targeting - The invention provides compositions and methods for delivering a therapeutic or diagnostic agent to a disease site in a mammal, the method comprising administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the therapeutic or diagnostic agent coupled to an albumin binding peptide and a pharmaceutically acceptable carrier. | 01-12-2012 |
| 20110150763 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS - The invention provides for Triazine derivatives and their use to modulate protein kinase activity in a variety of conditions and diseases. | 06-23-2011 |
| 20110076456 | LENS ARRAYS AND METHODS OF MAKING THE SAME - In general, in a first aspect, the invention features a method that includes depositing a first material on a surface of an article to form a layer including the first material. The surface of the article includes a plurality of protrusions and the layer including the first material forms a plurality of lenses. Each lens corresponds to a protrusion on the substrate surface. | 03-31-2011 |
| 20110009337 | Q3 SPARC DELETION MUTANT AND USES THEREOF - The invention provides for SPARC polypeptides with a mutation corresponding to a deletion of the third glutamine in the mature fault of the human SPARC protein, nucleic acids encoding such polypeptides, antibodies against such polypeptides, and methods of the use of such polypeptides, nucleic acids, and antibodies. | 01-13-2011 |
| 20100310507 | USE OF 2 ANTI-SPARC ANTIBODIES TO PREDICT RESPONSE TO CHEMOTHERAPY - The invention provides anti-SPARC antibody-based techniques for predicting a response to chemotherapy. | 12-09-2010 |
| 20100305148 | DI-ESTER PRODRUGS OF CAMPTOTHECIN, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL APPLICATIONS - The present invention is related to 10,20-di-O ester derivatives of camptothecin and pharmaceutical formulations thereof. The compounds and pharmaceutical formulations of the present invention possess increased biological life span and bioavailability and reduced toxicity, while maintaining anti-cancer activity. | 12-02-2010 |
| 20100279963 | DICARBONYL DERIVATIVES AND METHODS OF USE - Derivatives of dicarbonyl compounds having antitumor and antibiotic activity which can be used as anticancer agents. | 11-04-2010 |
| 20100112077 | NANOPARTICLES OF PACLITAXEL AND ALBUMIN IN COMBINATION WITH BEVACIZUMAB AGAINST CANCER - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 05-06-2010 |
| 20090280167 | ENHANCEMENT OF DRUG THERAPY BY MIRNA - This invention provides methods and compositions for screening of microRNA capable of modulating gene expression in the apoptotic pathway in the presence of HSP90 inhibitor. The use of miRNA for enhancing the activity of therapeutic agents not limited to HSP90 inhibitor is also disclosed. The diagnostic use of miRNA for predicting response to therapy not limited to therapeutic agents is also disclosed. A method for the identification and therapeutic application of small molecules which are modulators of these nucleic acids are also included in this application | 11-12-2009 |
| 20090220589 | TREATMENT, DIAGNOSTIC, AND METHOD FOR DISCOVERING ANTAGONIST USING SPARC SPECIFIC MIRNAS - miRNAs that regulate human SPARC and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, ds miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA. | 09-03-2009 |
